Chemical ablation formulations and methods of treatments for various diseases
Embodiments of the present invention are directed to the treatment of hypertension, diabetes, obesity, heart failure, end-stage renal disease, digestive disease, urological disease, cancers, tumors, pains, asthma, pulmonary arterial hypertension, and chronic obstructive pulmonary disease by delivering of an effective amount of formulations at desired temperature to target tissue. The formulations include gases, vapors, liquids, solutions, emulsions and suspensions of one or more ingredients. The temperature may enhance safety and efficacy of the formulations for the treatments. The amounts of the formulation and/or energy are effective to injury or damage the tissues to have a benefit of symptom relive.
1. A method of treating a disease, the method comprising:
inserting a needle-based balloon delivery catheter into a vascular lumen adjacent to a nerve, wherein the needle-based balloon delivery catheter comprises a balloon disposed along an elongated shaft and the balloon has a diameter in an inflated state in a range of from 2 millimeters to 30 millimeters;
inflating the balloon;
infusing a chemical formulation at a temperature and at a pressure from the needle-based balloon delivery catheter adjacent to the nerve, wherein an amount of the chemical formulation delivered is effective to injure or damage the nerve to have a benefit of relieving symptoms of the disease, wherein the chemical formulation is at least one of 10 wt % to 100 wt % ethanol and 1 wt % to 100 wt % acetic acid;
deflating the balloon; and
withdrawing the needle-based balloon delivery catheter from the body lumen, wherein the chemical formulation interacts with the nerve resulting in denervation;
wherein the disease is chosen from hypertension, diabetes, obesity, end-stage renal disease, heart failure, and a combination thereof.
2. The method of claim 1 , wherein the chemical formulation comprises at least one of a gas, vapor, liquid, solution, and an emulsion and/or suspension of one or more ingredients.
3. The method of claim 1 , wherein the temperature of the chemical formulation is in the range of −40° C. to 140° C.
4. The method of claim 1 , wherein the pressure of the formulation is in the range of 1 to 12 ATM.
5. The method of claim 1 , wherein the pressure of the chemical formulation is higher than the pressure of body lumen.
6. The method of claim 1 , wherein the amount of the chemical formulation is in the range of 0.2 microliters to 200 milliliters.
7. The method of claim 1 , wherein heat or energy is delivered from the chemical formulation adjacent to the nerve in an amount from about 2 cal/g to about 150 cal/g.
8. The method of claim 1 , wherein the needle-based balloon delivery catheter is a balloon catheter, a double-balloon catheter, or a combination of a balloon catheter and an infusion catheter.
9. The method of claim 1 , wherein the chemical formulation further comprises a therapeutic agent for nerve denervation, wherein the therapeutic agent is chosen from sodium channel blockers, tetrodotoxin, saxitoxin, decarbamoyl saxitoxin, vanilloids, neosaxitoxin, lidocaine, conotoxins, cardiac glycosides, digoxin, glutamate, staurosporine, amlodipine, verapamil, cymarin, digitoxin, proscillaridin, quabain, veratridine, domoic acid, oleandrin, carbamazepine, aflatoxin, guanethidine, guanethidine sulfate, and combinations thereof.
10. The method of claim 1 , wherein the chemical formulation comprises a contrast agent for imaging nerve denervation.
11. The method of claim 1 , wherein the method is a method of thermal and chemical ablation for treating a disease, wherein the infusing of the chemical formulation from the needle-based balloon delivery catheter adjacent to the nerve comprises delivering the chemical formulation and energy adjacent to the nerve, wherein the amount of energy and/or chemical formulation delivered is effective to injure or damage the nerve to relieve symptoms of the disease.
12. The method of claim 11 , wherein the energy is chosen from radiofrequency, cryoablation, microwave, laser, ultrasound, high intensity focused ultrasound, vapor condensation of at least some of the chemical formulation to a liquid, and combinations thereof.
13. The method of claim 11 , wherein the chemical formulation is infused to the nerve tissue during, before, or after the energy is delivered.
14. The method of claim 11 , wherein the chemical formulation comprises water or saline, wherein infusion of the chemical formulation from the needle-based balloon delivery catheter adjacent to the nerve is effective to decrease the temperature of the vascular lumen adjacent to the nerve.
15. The method of claim 1 , wherein the chemical formulation is 100% ethanol.
16. The method of claim 1 , wherein the chemical formulation is an azeotrope of ethanol and water.
17. The method of claim 1 , wherein the needle-based balloon delivery catheter further comprises a marker band located distally of the balloon.
18. The method of claim 1 , wherein the balloon comprises a material chosen from a polyamide, a nylon, a polyether block amide, a polyester, a polyethylene terephthalate, a polyurethane, a copolymer thereof, and a mixture thereof.
19. A method of treating a disease, the method comprising:
inserting a needle-based balloon delivery catheter into a vascular lumen adjacent to a nerve, wherein the needle-based balloon delivery catheter comprises a balloon disposed along an elongated shaft and the balloon has a diameter in an inflated state in a range of from 2 millimeters to 30 millimeters;
inflating the balloon;
infusing a chemical formulation at a temperature and at a pressure from the needle-based balloon delivery catheter adjacent to the nerve, and delivering heat and/or energy from the needle-based balloon delivery catheter adjacent to the nerve, wherein an amount of the heat and/or energy delivered combined with an amount of the chemical formulation delivered is effective to injure or damage the nerve resulting in denervation of the nerve and relief of symptoms of the treated disease, wherein the chemical formulation is at least one of 10 wt % to 100 wt % ethanol and 1 wt % to 100 wt % acetic acid;
deflating the balloon; and
withdrawing the needle-based balloon delivery catheter from the body lumen;
wherein the disease is chosen from hypertension, diabetes, obesity, end-stage renal disease, heart failure, and a combination thereof.
20. The method of claim 19 , wherein the heat and/or energy delivered adjacent to the nerve is sufficient to bring the temperature adjacent to the nerve to a range of −40° C. to 140° C.
21. The method of claim 19 , wherein the heat and/or energy delivered adjacent to the nerve is in an amount from about 2 cal/g to about 150 cal/g.
22. The method of claim 19 , wherein the energy is chosen from radiofrequency, cryoablation, microwave, laser, ultrasound, high intensity focused ultrasound, vapor condensation of at least some of the chemical formulation to a liquid, and combinations thereof.
23. The method of claim 19 , wherein the needle-based balloon delivery catheter further comprises a marker band located distally of the balloon.
24. The method of claim 19 , wherein the balloon comprises a material chosen from a polyamide, a nylon, a polyether block amide, a polyester, a polyethylene terephthalate, a polyurethane, a copolymer thereof, and a mixture thereof.
25. The method of claim 19 , further comprising infusing a chemical formulation comprising water or saline from the needle-based balloon delivery catheter adjacent to the nerve to decrease the temperature of the vascular lumen adjacent to the nerve.